< Back to search
Filter
1

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

for
B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma,
Location: St. John's, Halifax, Bangor ME, Scarborough ME,
Sponsor: Children's Oncology Group

Sex: All

Age: 1 - 25

Code: NCT03959085

Phase3, Recruiting

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

for
Acute Leukemia of Ambiguous Lineage,
Location: Scarborough ME, Boston MA, Providence RI, Worcester MA,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 0 - 1

Code: NCT06317662

Phase2, Recruiting
New

Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

for
Acute Myeloid Leukemia With Complex Karyotype,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT07582172

Phase2, Recruiting

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

for
Acute Myeloid Leukemia, Myelodysplastic Syndromes,
Location: New York NY, Hackensack NJ, Tampa FL, Houston TX,
Sponsor: Orca Biosystems, Inc.

Sex: All

Age: 12 - 70+

Code: NCT03802695

Phase1, Recruiting

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

for
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Location: Fairway KS
Sponsor: Celyad Oncology SA

Sex: All

Age: 18+

Code: NCT04167696

Phase1, Recruiting

Interested in new acute myeloid leukemia trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Venetoclax and Lintuzumab-Ac225 in AML Patients

for
Acute Myeloid Leukemia, Relapsed Adult AML
Location: New York NY, Louisville KY, New Orleans LA, Seattle WA,
Sponsor: Actinium Pharmaceuticals

Sex: All

Age: 18+

Code: NCT03867682

Phase1, Phase2, Recruiting

Tempus Open Link for Individual Voices in Innovative Analytics Registry: Platform Protocol for Multimodal Real-World Evidence in Cancer

for
Cancer, Solid Tumor Cancer, Pediatric Acute Myeloid Leukemia,
Location: Chicago IL
Sponsor: Tempus AI

Sex: All

Age: 0+

Code: NCT07756034

Recruiting

A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML

for
AML (Acute Myeloid Leukemia)
Location: Grand Rapids MI
Sponsor: Charm Therapeutics

Sex: All

Age: 18+

Code: NCT07751991

Phase1, Recruiting

Motixafortide for MRD Sensitization in AML

for
Acute Myeloid Leukemia, Measurable Residual Disease
Location: St Louis MO
Sponsor: Washington University School of Medicine

Sex: All

Age: 18+

Code: NCT07392970

Phase2, Recruiting

Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

for
Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia,
Location: Miami FL
Sponsor: Terrence J Bradley, MD

Sex: All

Age: 18+

Code: NCT05597306

Phase1, Recruiting

Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies

for
Leukemia, Acute, MDS
Location: Philadelphia PA
Sponsor: Abramson Cancer Center at Penn Medicine

Sex: All

Age: 60+

Code: NCT03680677

Recruiting